Table 2.
Treatment Administered
| Parameter | Paclitaxel | Carboplatin | Cetuximab |
|---|---|---|---|
| No. of doses | |||
| Median | 6 | 6 | 6 |
| Range | 4-6 | 4-6 | 1-8 |
| Dose-intensity* | |||
| Median | 810 | 12 | 1,650 |
| Range | 450-810 | 7-12 | 400-2,150 |
| Patients with ≥ 1 dose held for ≥ 7 days | |||
| No. of patients | 28 | 28 | 29 |
| % | 60 | 60 | 62 |
| Patients with dose reductions | |||
| No dose reduction | |||
| No. of patients | 43 | 45 | 46 |
| % | 91 | 96 | 98 |
| Dose level −1† | |||
| No. of patients | 4 | 2 | 1 |
| % | 9 | 4 | 2 |
| Dose density‡ | |||
| Median | 135 | 2 | 275 |
| Range | 75-135 | 1.2-2 | 67-358 |
Abbreviation: AUC, area under the curve.
*
Total dose delivered during the induction program. Units of measure are as follows: carboplatin, AUC; paclitaxel, mg/m2; and cetuximab, mg/m2.
†
Dose level −1 was as follows: carboplatin AUC 1.5/wk, paclitaxel 90 mg/m2/wk, and cetuximab 200 mg/m2/wk.
‡
Dose delivered per week during the induction program, accounting for treatment delays and dose reductions. Units of measure are as follows: carboplatin, AUC/wk; paclitaxel, mg/m2/wk; and cetuximab, mg/m2/wk. The loading dose of cetuximab (ie, 400 mg/m2) was included in the calculation of dose density.